Table 1.
Patient demographics of CxBladder surveillance.
| No (%) | Positive CxBladder | Negative CxBladder | |
|---|---|---|---|
| Median age + IQR | 70 (59–74) | ||
| Gender | |||
| Male | 23 (82%) | 12 (43%) | 11 (39%) |
| Female | 5 (18%) | 3 (11%) | 2 (7%) |
| Race | |||
| Chinese | 17 (61%) | 9 (32%) | 8 (29%) |
| Malay | 4 (15%) | 3 (12%) | 1 (3%) |
| Indian | 6 (21%) | 2 (7%) | 4 (14%) |
| Others | 1 (3%) | 1 (3%) | |
| Risk | |||
| Smoker | 17 (61%) | 9 (32%) | 8 (29%) |
| Bladder Ca Staging | |||
| Ta | 15 (54%) | 8 (29%) | 7 (25%) |
| T1 | 13 (46%) | 7 (25%) | 6 (21%) |
| Bladder Ca grading | |||
| High grade | 18 (64%) | 8 (29%) | 10 (35%) |
| Low grade | 10 (36%) | 7 (25%) | 3 (11%) |
| Bladder Ca risk group | |||
| Low risk | 9 (32%) | 4 (14%) | 5 (18%) |
| Intermediate risk | 7 (25%) | 4 (14%) | 3 (11%) |
| High risk | 12 (43%) | 7 (25%) | 5 (18%) |
| Previous intravesical therapy | |||
| Mitomycin | 10 (35%) | 4 (14%) | 6 (21%) |
| BCG | 15 (54%) | 8 (29%) | 7 (25%) |
| N/A | 3 (11%) | 3 (11%) | |